Protalix BioTherapeutics, Inc. (NYSEMKT:PLX) Files An 8-K Results of Operations and Financial Condition
Item 2.02. Results of Operations and Financial Condition
On January 9, 2017, Protalix BioTherapeutics, Inc. (the Company)
issued a press release providing a review of 2016 and its
strategic outlook for 2017. A copy of the press release is
furnished as Exhibit 99.1 to this Current Report on Form 8-K.
Item 7.01. Regulation FD Disclosure
On January 9, 2017, the Company posted a copy of its January 2017
Corporate Update in the Presentations page of the Investors tab
of its corporate website. A copy of the corporate update is
furnished as Exhibit 99.2 to this Current Report on Form 8-K.
All of the information furnished in Items 2.01 and 7.01, and
Exhibits 99.1 and 99.2, shall not be deemed to be filed for
purposes of Section18 of the Securities Exchange Act of 1934, as
amended (the Exchange Act), or otherwise subject to the liability
of that section, and shall not be incorporated by reference into
any registration statement or other document filed under the
Securities Act of 1933, as amended, or the Exchange Act, except
as shall be expressly set forth by specific reference in such
filing.
Item 9.01. Financial Statements and Exhibits
| (d) | Exhibits |
| 99.1 | Press release dated January 9, 2017. |
| 99.2 | January 2017 Corporate Update. |
About Protalix BioTherapeutics, Inc. (NYSEMKT:PLX)
Protalix BioTherapeutics, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of recombinant therapeutic proteins based on its ProCellEx protein expression system (ProCellEx). The Company has developed taliglucerase alfa (marketed under the name Uplyso in Brazil and certain other Latin American countries and Elelyso in the rest of the territories) for the treatment of Gaucher disease that has been approved for marketing in the United States, Brazil, Israel and other markets. The Company’s product pipeline includes PRX-102 for the treatment of Fabry disease; AIR DNase (PRX-110) for Cystic Fibrosis, and Oral Anti-TNF (OPRX-106) Anti Inflammatory. PRX-102 or alpha-GAL-A is an enzyme replacement therapy product for the treatment of Fabry disease. AIR DNase is a plant cell recombinant human Deoxyribonuclease 1. Oral Anti-TNF represents a mode of administering a recombinant anti-TNF protein. Protalix BioTherapeutics, Inc. (NYSEMKT:PLX) Recent Trading Information
Protalix BioTherapeutics, Inc. (NYSEMKT:PLX) closed its last trading session up +0.005 at 0.420 with 2,421,103 shares trading hands.
